Flemo Max20 mg+35 mg+200 mg+50 mg+50 mg

Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg is formulated to support overall joint health, mobility, and inflammatory balance. Based on the official reference, it is primarily indicated in the following conditions:

Primary Indications

• Osteoarthritis
  Helps support joint cartilage health, reduce stiffness, and improve day-to-day joint function in degenerative joint conditions.
• Rheumatoid Arthritis Used as supportive therapy to help manage joint inflammation, pain, and progressive joint discomfort associated with autoimmune arthritis.

Additional Indications

• Joint pain and inflammation
  May help reduce inflammatory discomfort in joints caused by overuse, aging, or chronic musculoskeletal stress.
• Reduced flexibility and mobility
  Supports improved joint movement and range of motion, especially in weight-bearing joints such as knees, hips, and spine.
• Joint stiffness (including knee extension difficulty)
  Helps improve morning stiffness and difficulty in bending or extending joints, promoting smoother movement during daily activities.

Supportive Joint Health Benefits (Expanded Information)

In addition to the primary indications, Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg may also provide supportive benefits such as:

• Maintenance of cartilage integrity and joint cushioning
• Support for synovial fluid viscosity (due to hyaluronic acid)
• Anti-inflammatory support (from Boswellia serrata and turmeric extract)
• Assistance in collagen structure maintenance for joint resilience
• Improvement in overall joint comfort during physical activity and aging-related wear and tear

Each capsule of Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg support formulation contains a scientifically balanced blend of cartilage-supporting, anti-inflammatory, and mobility-enhancing ingredients:

Active Ingredients per Capsule

• Undenatured Type-II Collagen – 20 mg
  A specialized form of collagen that helps support cartilage structure, joint integrity, and immune-mediated joint tolerance. Commonly used in joint nutrition formulations for osteoarthritis support.
• Hyaluronic Acid – 35 mg
  A key component of synovial fluid that helps maintain joint lubrication, shock absorption, and smooth movement of joints.
• Methylsulfonylmethane (MSM) – 200 mg
  A natural sulfur-containing compound that supports connective tissue health, helps reduce joint discomfort, and promotes flexibility.
• Turmeric Extract – 50 mg (18% curcuminoids)
  A potent botanical extract known for its antioxidant and anti-inflammatory properties, supporting joint comfort and inflammatory balance.
• Boswellia serrata Extract – 50 mg (30% AKBA)
  Standardized extract that helps modulate inflammatory pathways and supports improved joint mobility and comfort.

Formulation Overview (Expanded Insight)

Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg is designed to provide a multi-targeted approach to joint care by:

• Supporting cartilage regeneration and structural integrity (Type-II collagen, MSM)
• Enhancing synovial fluid quality for better lubrication (Hyaluronic Acid)
• Reducing inflammatory mediators associated with joint pain (Turmeric, Boswellia serrata)
• Improving overall joint flexibility, cushioning, and mobility

The Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg works through complementary biological mechanisms targeting cartilage preservation, inflammation control, and joint lubrication. Each component contributes uniquely to overall musculoskeletal support.

1. Undenatured Type-II Collagen (UC-II Mechanism of Action)

Undenatured Type-II Collagen is derived from chicken sternum cartilage using a patented, low-temperature, non-enzymatic process that preserves its native triple-helix structure and biological activity.

It contains specific active binding sites known as epitopes, which play a key role in the process of oral tolerization.

Immunological Mechanism

• After oral intake, collagen epitopes interact with Peyer’s patches in the small intestine (gut-associated lymphoid tissue).
• This interaction stimulates the production of collagen-specific regulatory T-cells (T-reg cells).
• These regulatory cells migrate to joint tissues and help modulate immune response.
• They reduce the activity of T-cells responsible for attacking joint cartilage, thereby supporting immune balance in autoimmune and degenerative joint conditions.

Chondroprotective Effects

• Inhibits release of collagenase enzymes from macrophages that degrade cartilage matrix.
• Reduces inflammatory cytokine production involved in joint degeneration.
• Helps slow cartilage breakdown and supports long-term joint structural integrity.
• Promotes a protective environment for cartilage preservation and repair.

2. Hyaluronic Acid Mechanism (Joint Lubrication & Tissue Support)

Hyaluronic acid is a naturally occurring glycosaminoglycan widely distributed in connective tissues, especially synovial fluid.

Key Pharmacological Actions

• Joint Lubrication: Forms a highly viscous, gel-like matrix by binding water molecules, enhancing synovial fluid viscosity.
• Shock Absorption: Acts as a mechanical buffer, reducing friction between articular surfaces.
• Cartilage Support: Facilitates chondrocyte function and supports cartilage matrix maintenance.
• Anti-inflammatory Role: Helps reduce local inflammatory response and joint pain caused by degeneration or injury.

3. Methylsulfonylmethane (MSM) Mechanism of Action

MSM is an organic sulfur-containing compound with significant roles in connective tissue metabolism.

Pharmacological Effects

• Exhibits anti-inflammatory and antioxidant properties.
• Provides sulfur, an essential element required for synthesis of collagen, glucosamine, and keratin.
• Supports structural integrity of cartilage, tendons, and ligaments.
• Clinical studies have shown improvement in WOMAC pain scores and physical function in osteoarthritis patients.
• Helps reduce oxidative stress-induced joint damage.

4. Turmeric Extract (Curcumin Mechanism)

Turmeric contains curcuminoids, primarily curcumin, responsible for its pharmacological activity.

Anti-inflammatory & Antioxidant Actions

• Inhibits key inflammatory mediators including:
  • Prostaglandins
  • Leukotrienes
  • Cyclooxygenase-2 (COX-2)
• Downregulates pro-inflammatory cytokines such as:
  • Tumor Necrosis Factor-alpha (TNF-α)
  • Interleukins (IL-1, IL-8)
• Suppresses nitric oxide synthase activity, reducing oxidative inflammatory damage.
• Exhibits antioxidant and antimicrobial properties that contribute to tissue protection and recovery.

5. Boswellia serrata (5-LOX Pathway Inhibition)

Boswellia serrata contains active boswellic acids, with 3-O-acetyl-11-keto-beta-boswellic acid (AKBA) being the most potent.

Pharmacological Mechanism

• Potently inhibits 5-lipoxygenase (5-LOX) enzyme, a key mediator in leukotriene synthesis.
• Reduces production of inflammatory leukotrienes involved in chronic joint inflammation.
• Provides significant anti-inflammatory activity in conditions like osteoarthritis and rheumatoid arthritis.
• Supports reduction of joint swelling, stiffness, and pain.
• Helps preserve joint function by controlling inflammatory cascades.

Overall Pharmacological Synergy

Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg provides a multi-pathway approach to joint health:

• Immune modulation: UC-II regulates autoimmune-driven cartilage damage
• Structural support: MSM and collagen pathways maintain cartilage integrity
• Lubrication & cushioning: Hyaluronic acid improves synovial fluid function
• Inflammation control: Turmeric and Boswellia target multiple inflammatory pathways
• Oxidative protection: Antioxidant activity helps prevent long-term joint degeneration

There is no known drug interaction with Undenatured type II Collagen, Hayaluronic Acid, Methylsulfonylmethane, Turmeric Extract and Boswellia serrata Extract

Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg support formulation is generally considered well tolerated when used at the recommended dosage, with a low incidence of adverse effects.

Overall Tolerability

Most individuals use Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg without experiencing significant side effects. The ingredients are widely used in nutraceuticals for joint health and have a favorable safety profile in clinical and post-market use.

Possible Side Effects (Rare and Mild)

Although uncommon, some individuals may experience mild and temporary effects such as:

• Gastrointestinal discomfort
  • Mild stomach upset
  • Nausea
  • Bloating
  • Indigestion
• Gastric irritation (rare)
  • May occur in sensitive individuals, particularly when taken on an empty stomach

Ingredient-Specific Considerations (Low Incidence)

• Turmeric Extract: May occasionally cause mild gastric irritation in sensitive individuals
• Boswellia serrata: Rare cases of mild nausea or digestive discomfort
• MSM (Methylsulfonylmethane): Occasionally associated with mild bloating or loose stools in some users
• Undenatured Type-II Collagen & Hyaluronic Acid: Generally very well tolerated with minimal reported adverse effects

Frequency and Severity

• Side effects are typically rare, mild, and self-limiting
• Most symptoms resolve without discontinuation or with minor adjustment (e.g., taking with food)

Safety Summary

• High overall tolerability profile
• No serious or life-threatening side effects commonly reported at recommended doses
• Gastrointestinal discomfort is the most commonly observed mild complaint

The safety of Flemo Max 20 mg+35 mg+200 mg+50 mg+50 mg during pregnancy and breastfeeding has not been fully established through well-controlled clinical studies. Therefore, its use requires careful consideration.

Pregnancy

• There are no adequate or well-controlled studies evaluating the safety of:
  • Undenatured Type-II Collagen
  • Hyaluronic Acid
  • Methylsulfonylmethane (MSM)
  • Turmeric Extract
  • Boswellia serrata Extract
• Due to limited clinical data, use during pregnancy should be approached with caution.
• Supplementation should only be considered if:
  • Clearly recommended by a qualified healthcare professional
  • The potential benefits outweigh any possible risks

Lactation (Breastfeeding)

• Safety data during breastfeeding is also insufficient
• It is unknown whether any of the active components are excreted in breast milk in clinically significant amounts
• Therefore, caution is advised when administering during lactation

Clinical Recommendation

• Use during pregnancy and breastfeeding should be:
  • Medically supervised
  • Individually assessed based on maternal health needs
• Self-medication is generally not recommended in these populations due to lack of established safety evidence

Safety Summary

• No confirmed evidence of harm, but also no definitive safety studies
• Use only under medical guidance during pregnancy and lactation
• Prefer non-pharmacological or well-established alternatives when appropriate

Store in a cool & dry place below 30° C, protected from direct sunlight & moisture. Keep out of the reach of children.